UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%

Utah Medical Products (UTMD) reported a Q2 2025 earnings decline, with EPS down 4% to $0.94 and net sales falling 4.3% to $10 million, resulting in a 3% stock drop. This performance was largely attributed to a 38% decrease in OEM domestic sales (driven by PendoTECH orders) and a 10.5% decline in international sales, which also pressured gross profit margins to 56.2%. Despite strength in direct domestic sales and reduced operating expenses, management anticipates continued PendoTECH weakness will impact full-year 2025 results, though they project a realistic trailing twelve-month EBITDA target of $16 million to $18 million.

Analysis

Utah Medical Products (UTMD) reported a challenging second quarter for 2025, with net sales declining 4.3% year-over-year to $10 million and earnings per share falling 4% to $0.94. The top-line weakness was primarily driven by a significant 38% drop in domestic OEM sales, resulting from a sharp decline in PendoTECH orders, and a 10.5% decrease in international sales, which the company attributes to distributor order timing and potential tariff issues. This contraction overshadowed the resilience in the core domestic direct sales channel, where sales grew 0.6% on the back of a 10% increase in non-Filshie device sales. Profitability was significantly impacted, with gross profit margin contracting 390 basis points to 56.2% due to lower sales volume and an unfavorable product mix. While a 14.8% reduction in operating expenses, driven by lower litigation costs, helped cushion the blow to operating income, net income still fell 11.7%. Management has signaled that PendoTECH weakness will persist, forecasting a $2 million negative impact for the full year and guiding to a trailing-twelve-month EBITDA target of $16 to $18 million, below the current $18.6 million. Despite these headwinds, the company maintains a strong balance sheet with $82.2 million in cash and investments and continued shareholder returns through $1 million in dividends and a repurchase of 64,988 shares.

Key Decisions for Investors

• Investors should weigh the persistent, anticipated weakness in the OEM segment against the underlying strength in domestic direct sales when assessing the company's near-term growth profile.
• Monitor gross profit margins closely, as management's guidance for a lower full-year EBITDA suggests profitability will remain under pressure despite disciplined operating expense control.
• Consider the company's commitment to capital returns, evidenced by consistent dividends and share buybacks, as a potential valuation support, particularly given the strong cash position and recent stock underperformance.
• Watch for signs of normalization in international distributor demand and any updates on tariff-related disruptions, as a recovery in this segment could provide a significant catalyst.